Comparison of outcomes for tAML/tMDS and de novo AML/MDS
| . | AML/MDS, n = 960 . | tAML/tMDS, n = 24 . | Log-rankP . |
|---|---|---|---|
| Remission rate | 72.4% | 50.0% | .016 |
| Survival at 3 y | 47% ± 3% | 26% ± 18% | .007 |
| EFS at 3 y | 39% ± 3% | 21% ± 17% | .023 |
| DFS at 3 y | 53% ± 4% | 45% ± 30% | .868 |
| . | AML/MDS, n = 960 . | tAML/tMDS, n = 24 . | Log-rankP . |
|---|---|---|---|
| Remission rate | 72.4% | 50.0% | .016 |
| Survival at 3 y | 47% ± 3% | 26% ± 18% | .007 |
| EFS at 3 y | 39% ± 3% | 21% ± 17% | .023 |
| DFS at 3 y | 53% ± 4% | 45% ± 30% | .868 |